The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2019 | Updates on German clinical trials in multiple myeloma
Marc Raab, MD, PhD, of University Hospital Heidelberg, Heidelberg, Germany, gives an overview of recently concluded and ongoing German clinical trials looking at multiple myeloma (MM) treatment. For example, Prof. Raab discusses the results from the GMMG-MM5 trial (EudraCT no. 2010-019173-16), which compares a fixed two-year period of lenalidomide maintenance with stopping maintenance after complete remission. Prof. Raab also explains how two ongoing trials are likely to present interesting results on the role of monoclonal antibodies in first-line setting. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
